Home > Oncology > ESMO 2019 > Lung Cancer > First-line osimertinib significantly lengthens OS in NSCLC

First-line osimertinib significantly lengthens OS in NSCLC

Presented By
Prof. Suresh Ramalingam, Emory University, Atlanta, USA
Conference
ESMO 2019
Trial
Phase 3, FLAURA
Prof. Suresh Ramalingam (Emory University, Atlanta, USA) presented the final overall survival (OS) data of the FLAURA trial in the first Presidential Symposium. First-line osimertinib significantly lengthened overall survival compared with first generation EGFR TKIs (gefitinib or erlotinib) in patients with advanced non–small cell lung cancer (NSCLC) harbouring Ex19del/L858R EGFR mutation [1]. The primary endpoint of progression free survival (PFS) was previously reported [2]. Final overall survival results were presented (58% maturity): the median OS with osimertinib was 38.6 months vs 31.8 months with first generation EGFR TKIs, with a hazard ratio of 0.799 (P=0.0462; see Table). More than half (54%) of patients in the osimertinib group were alive at 3 years compared with 44% in the standard care group. Table. Efficacy results of the FLAUR...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on